What we do [00]

We are the European experts in the cultivation and supply of medical cannabis products, from plant to patient.

With a cultivation facility located in Northern Greece, we are in prime position for European distribution.

The medical cannabis market in Europe was worth €4.1bn in 2019 and is expected to reach €43.3bn by 2027

JUMP TO

The Facility [01]

Hellenic Dynamics operates from a secure, custom designed 195,506 square meter facility located just 48 miles from Thessaloniki, Greece’s second largest city, which has daily direct flights to all major target markets across Europe.

The facility has been designed to produce the highest quality dried medical cannabis flowers and extracts with one of the lowest costs of production in Europe. This is underpinned by access to some of the most competitive utilities in Europe and the site having its own dedicated water supply by way of a number of underground reservoirs. Based near the town of Kilkis, Hellenic Dynamics is also able to leverage a large skilled local workforce, bringing much needed employment to the area.

Previously a United Nations military facility, the site consists of 14 buildings and uniquely a number of over ground bunkers where initial plant cultivation is housed. Construction is also due to begin on a 10,000 square meter fully enclosed greenhouse, which Hellenic intents to use via a phased approach utilizing revues to expand overall cultivation area.

All dried flowers to be produced in phase one of operations have been presold to licensed distributors – initially in Europe’s largest medical cannabis market of Germany with further distribution lines into other European markets underway.

The facility will adhere to all relevant EU regulations including Good Manufacturing Practice (“GMP”) and Good Agricultural Collection Practice (“GACP”) for end products.

Hellenic Dynamics

[01] Office, admin, security

[02] Trimming and drying room

[03, 04] Storage

[05] Clone room

[06] Mother room

[07, 08, 09, 10, 11] Cultivation bunker

[12] Second power sub station

[13] Water pump room and tank

[14] Main power sub station

[15] Perimeter fencing

Cultivation [02]

Hellenic Dynamic’s lead products are THC dominant dried medical cannabis flowers which occupy the largest market share of European prescriptions and are also the most under supplied. An extraction facility has been planned to be operational when European demand for medical cannabis extracts is deemed to be significant enough for the production and sales of both THC flowers and oils. The cultivation strategy is based on several phases with each phase increasing the total cultivation area based on growing European demand for medical cannabis products.

AND BEYOND

The Hellenic Dynamics cultivation licence allows a total of 40,000 square meters of active medical cannabis cultivation area. At full production this could produce over 54,000 kg of dried flowers per annum. With ample space on the facility to increase production, Hellenic Dynamics can be the dominant supplier of medical cannabis flowers within Europe by the high quality of its finished products coupled with one of the lowest costs of production in Europe.

Hellenic Dynamics

Medical innovation [03]

Medical cannabis, especially in higher THC doses, has been approved for use in the United Kingdom and Germany plus 24 other European countries for conditions including but not limited to chronic pain, Spinal cord treatment, Anxiety, HIV/AIDS Appitite loss, Multiple Sclerosis, Crohn’s disease, PTSD, Chemotherapy side effects, Glaucoma, Anorexia, Lennox- Gastaut syndrome, Alzheimer’s, Dravet syndrome, Tourette’s syndrome, Intractable spasticity and Cachexia.

Hellenic Dynamics strongly believes that controlling every aspect of the cultivation cycle of medical cannabis flowers is the best way to maximize the benefit of this medicine to patients. Specific cannabis genetics have also been shown to have differing effects against certain pain indicators. To address this issue, Hellenic Dynamics has formed several partnerships to begin research and development studies of our genetics in order to conduct efficacy trials against pain indictors in patients. This will allow Hellenic Dynamics to be at the forefront of the next evolution of the medical cannabis industry by way of registering certain strains at the E.U. level to produce IP protected genetics.

Laboratory [04]


Warning: Trying to access array offset on value of type bool in /home/fedrigon/public_html/wp-content/themes/hellenicdynamics/partials/what-we-do/laboratory.php on line 22

Warning: Trying to access array offset on value of type bool in /home/fedrigon/public_html/wp-content/themes/hellenicdynamics/partials/what-we-do/laboratory.php on line 22

Warning: Trying to access array offset on value of type bool in /home/fedrigon/public_html/wp-content/themes/hellenicdynamics/partials/what-we-do/laboratory.php on line 22

Germany legalised the use of medical cannabis in 2017. As such, it has the most advanced import and distribution legislation in Europe coupled with the highest standards for product specification.

The Hellenic Dynamics facility has been constructed from the ground up with this product specification in mind. A state-of-the-art laboratory has been designed to assist the cultivation team to ensure all products that leave the facility are of the highest possible quality and adhere to all requirements for import, not only in Germany, but all other target markets across Europe.

This means that testing for all the parameters required in each target market are conducted on site to ensure product compliance. A separate, second series of the same tests are conducted by our customers on products landing in our target markets.

Hellenic Dynamics

Disclaimer

The information on this website is being made available by Hellenic Dynamics PLC (“LON:HELD”) in good faith and for information purposes only. Please read this notice carefully - it applies to all persons who view this Website. Please note that this notice may be altered or updated. You should therefore read it in full each time you visit this Website. The information contained on this Website is not comprehensive and much of it is historical. No reliance may be placed for any purpose whatsoever on the suitability of the shares of LON:HELD for any prospective investor and LON:HELD, its directors, shareholders, advisers, affiliates, agents, representatives and employees assume no responsibility to you or any third party for the consequences of any errors or omissions. Neither LON:HELD, its directors, shareholders, advisers, affiliates, agents, representatives nor employees accept any liability for any direct or indirect or consequential loss or damages of any kind resulting from any use of this Website or any information contained on it. Some of the statements contained on this Website and in documents accessed through this Website may be forward looking statements. Actual results may differ from those expressed in such statements, depending on a variety of factors. The past performance of LON:HELD or its shares cannot be relied on as a guide to future performance. The price of the shares may go down as well as up and it may be that investors do not recoup the amount originally invested. This Website and the information on it does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in LON:HELD, nor shall it (or any part of it) or the fact of its distribution form the basis of, or be relied on in connection with or act as an inducement to enter into any contract or commitment therefor and any decisions you make based on the information contained on this Website are your sole responsibility having, where appropriate, taken independent advice as to the investment decision and any laws or regulations applicable to such investment decision. The information contained in this section of the Website is not directed at, nor is it intended for access by, persons located or resident in the United States, Australia, Canada, the Republic of South Africa, or Japan or any other jurisdiction in which it may be unlawful to receive or view such information. If you are not permitted to view the information (or are in any doubt as to whether you are permitted to view the information), please exit this Website. Any shares of LON:HELD referred to in the information on this Website have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended. Such shares have also not been registered under the applicable securities laws of Australia, Canada, the Republic of South Africa or Japan and may not be offered or sold in Australia, Canada, the Republic of South Africa or Japan or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration thereof in, such jurisdiction. LON:HELD, its directors, shareholders, advisers, affiliates, agents, representatives and employees (whether or not involved in creating, producing, maintaining or delivering this Website) exclude all liability and responsibility for any amount or kind of loss party in connection with this Website in or the information contained on it.

By clicking [Accept] you accept you have read the terms of this Important Notice.